The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CAH | +46.41% | +272.66% | +30.06% | +27,758% |
| S&P | +16.9% | +95.99% | +14.39% | +4,411% |
Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1971 and is headquartered in Dublin, OH.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $60.16B | 0.5% |
| Gross Profit | $2.20B | 21.7% |
| Gross Margin | 3.66% | 0.6% |
| Market Cap | $40.10B | 67.4% |
| Market Cap / Employee | $0.69M | 0.0% |
| Employees | 57.7K | 18.0% |
| Net Income | $243.00M | 4.3% |
| EBITDA | $927.00M | 29.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.87B | -24.5% |
| Accounts Receivable | $13.24B | 9.6% |
| Inventory | 16.8K | 12.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.63B | 70.6% |
| Short Term Debt | $714.00M | 29.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.18% | 1.3% |
| Return On Invested Capital | 3.30% | 7.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.30B | -31.3% |
| Operating Free Cash Flow | $1.53B | -26.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 21.48 | 22.08 | 21.51 | 26.09 | -7.98% |
| Price to Book | -8.39 | -8.73 | -11.15 | -13.62 | 38.32% |
| Price to Sales | 0.12 | 0.13 | 0.15 | 0.18 | 70.70% |
| Price to Tangible Book Value | -2.79 | -2.96 | -3.20 | -2.88 | -12.59% |
| Price to Free Cash Flow TTM | 8.75 | 47.92 | 17.09 | 29.73 | 63.23% |
| Enterprise Value to EBITDA | 39.75 | 43.02 | 41.16 | 49.56 | 44.84% |
| Free Cash Flow Yield | 11.4% | 2.1% | 5.9% | 3.4% | -38.74% |
| Total Debt | $5.16B | $7.61B | $7.68B | $9.35B | 66.61% |
CAH earnings call for the period ending September 30, 2021.
CAH earnings call for the period ending June 30, 2021.
CAH earnings call for the period ending March 31, 2021.
CAH earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
